UPSTREAM BIO, INC. Operating Expenses
UPSTREAM BIO, INC. (UPB) reported Operating Expenses of $43.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- UPSTREAM BIO, INC. operating expenses for the quarter ending 2026-06-30 was $43.14M, a 4.73% decline year-over-year.
- UPSTREAM BIO, INC. operating expenses for the quarter ending 2026-03-31 was $44.65M, a 37.05% increase year-over-year.
- UPSTREAM BIO, INC. operating expenses for the quarter ending 2025-12-31 was $46.84M, a 73.91% increase year-over-year.
- UPSTREAM BIO, INC. operating expenses for the quarter ending 2025-09-30 was $38.52M, a 97.52% increase year-over-year.
- UPSTREAM BIO, INC. operating expenses for fiscal 2025 was $163.22M, a 103.68% increase from fiscal 2024.
- UPSTREAM BIO, INC. operating expenses for fiscal 2024 was $80.13M, a 88.58% increase from fiscal 2023.
- UPSTREAM BIO, INC. operating expenses for fiscal 2023 was $42.49M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.14M 10-Q · filed 2026-08-11 | $87.79M 10-Q · filed 2026-08-11 | $134.63M derived: sum of 3 quarters · filed 2026-08-11 | $173.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $44.65M 10-Q · filed 2026-05-13 | $91.48M derived: sum of 2 quarters · filed 2026-05-13 | $130.00M derived: sum of 3 quarters · filed 2026-05-13 | $175.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $46.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $85.35M derived: sum of 2 quarters · filed 2026-03-26 | $130.64M derived: sum of 3 quarters · filed 2026-08-11 | $163.22M 10-K · filed 2026-03-26 |
| 2025-09-30 | $38.52M 10-Q · filed 2025-11-05 | $83.80M derived: sum of 2 quarters · filed 2026-08-11 | $116.38M 10-Q · filed 2025-11-05 | $143.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $45.28M 10-Q · filed 2026-08-11 | $77.86M 10-Q · filed 2026-08-11 | $104.79M derived: sum of 3 quarters · filed 2026-08-11 | $124.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $32.58M 10-Q · filed 2026-05-13 | $59.51M derived: sum of 2 quarters · filed 2026-05-13 | $79.01M derived: sum of 3 quarters · filed 2026-05-13 | $97.06M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $26.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $46.43M derived: sum of 2 quarters · filed 2026-03-26 | $64.48M derived: sum of 3 quarters · filed 2026-03-26 | $80.13M 10-K · filed 2026-03-26 |
| 2024-09-30 | $19.50M 10-Q · filed 2025-11-05 | $37.55M derived: sum of 2 quarters · filed 2025-11-05 | $53.20M 10-Q · filed 2025-11-05 | $67.98M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $18.05M 10-Q · filed 2025-08-06 | $33.70M 10-Q · filed 2025-08-06 | $48.48M derived: sum of 3 quarters · filed 2025-08-06 | $58.49M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $15.65M 10-Q · filed 2025-05-06 | $30.43M derived: sum of 2 quarters · filed 2025-05-06 | $40.44M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $24.79M derived: sum of 2 quarters · filed 2025-03-12 | $42.49M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $10.01M 10-Q · filed 2024-11-07 | $27.71M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |